Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate and is approved as a treatment option for several advanced cancers. T-DXd–related pneumonitis has been noted as an adverse event of special ...

Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus ...

Trastuzumab deruxtecan (DS-8201) ... (21% and 11%). A total of 12 patients had trastuzumab deruxtecan–related interstitial lung disease or pneumonitis ...

Trastuzumab deruxtecan reduced risk for disease progression or death compared with trastuzumab emtansine among patients with HER2-positive metastatic breast cancer previously treated with ...

Lung disease as an adverse effect of the targeted cancer drug trastuzumab deruxtecan (T-DXd, Enhertu) is not negligible, although the benefit-to-risk relationship with use of the drug is still ...

High-level results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) demons ...

Trastuzumab deruxtecan (6.4 mg/kg) is approved in several countries for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ ...

Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced/Recurrent Uterine Carcinosarcoma (NCCH1615): STATICE Trial — An ASCO Reading Room selection.

Primary data from the phase 3 DESTINY-Breast02 trial, which is currently investigating trastuzumab deruxtecan (T-DXd), a human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate ...

Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate approved for the treatment of several advanced cancers; however, severe or fatal interstitial lung disease/pneumonitis can occur. We ...